The Observation on Clinical Efficacy of Hemoperfusion in Treatment of 31 Patients with Severe Liver Diseases

Objective In order to study the clinical efficacy of hemoperfusion in severe liver diseases. Methods 31 patients with severe liver diseases were treated with HA hemoperfusion cartridge for 66 times.The results of serum endotoxin, cell factors, liver function,renal function,electrolyte,prothrombin time activity(PTA),blood ammonia, blood routine before and after the treatment were analyzed. The effective rate of hemoperfusion group was compared to the control group.Results After hemoperfusion,symptoms of patients with severe liver diseases were improved.Serum endotoxin,tumor necrosis factor alpha (TNF-α),interleukin-6 (IL-6)obviously reduced(P0.01),serum bilirubin,blood ammonia also obviously reduced than before(P0.05 or P0.01).The effective rate of hemoperfusion group was significantly higher than control group(P0.05).Blood platelet(PLT) reduced(P0.05),the side effects were mild.Conclusion Serum bilirubin,endotoxin, cell factors can be absorbed by hemoperfusion,which is comparatively safe and effective in the treatment of severe liver diseases. And hemoperfusion can elevate the survival rate of patients with severe liver diseases in early or middle period.